By Tom Crosby, RESI Conference Manager, LSN
At the upcoming RESI Conference on January 13, 2015 in San Francisco, leaders from the top venture philanthropy organizations from around the world will discuss their experience with impact investing. Venture philanthropy is one of the most talked about funding models in early stage life science investments today. Because venture philanthropy organizations typically fund on a multiyear basis, these heavily donor-funded organizations are working towards making significant results possible on a quick time line.
LSN is pleased to announce the representatives for the biotech track of venture philanthropy. The complementary session on venture philanthropy in the medical-device space will be announced at a later date.
Moderated by Brian Horsburgh, Trustee of the NeuroNetworks Fund, the audience will hear from:
- Ross Tonkens, Director, Science and Technology Accelerator, American Heart Association
- Lindy Fishburne, Executive Director, Breakout Labs
- Maria Berkman, Director, Broadview Ventures
- Tom Capetan, Business Development, Foundation Fighting Blindness
Panelists will address the following important questions on investing for impact: What do venture philanthropy investors look for in initial correspondence? What goes into the process of investment selection and due diligence? What value can venture philanthropists bring to your company in addition to capital? The session will also cover the metrics that are most important in evaluating progress and how grantees and donors are involved in analyzing these results.
If venture philanthropy investment is part of the plan to get your company funded, this panel presents a great opportunity to broaden your network while updating your understanding of these organizations.
Next Phase Newsletter 
Leave a comment